Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

C4 Therapeutics (CCCC) EPS (Basic) (2019 - 2025)

Historic EPS (Basic) for C4 Therapeutics (CCCC) over the last 7 years, with Q3 2025 value amounting to -$0.44.

  • C4 Therapeutics' EPS (Basic) fell 2571.43% to -$0.44 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.67, marking a year-over-year increase of 176.47%. This contributed to the annual value of -$1.52 for FY2024, which is 4314.19% up from last year.
  • Per C4 Therapeutics' latest filing, its EPS (Basic) stood at -$0.44 for Q3 2025, which was down 2571.43% from -$0.37 recorded in Q2 2025.
  • In the past 5 years, C4 Therapeutics' EPS (Basic) registered a high of -$0.26 during Q2 2024, and its lowest value of -$0.76 during Q4 2022.
  • Its 5-year average for EPS (Basic) is -$0.52, with a median of -$0.51 in 2021.
  • Its EPS (Basic) has fluctuated over the past 5 years, first skyrocketed by 9709.4% in 2021, then tumbled by 14516.13% in 2022.
  • Over the past 5 years, C4 Therapeutics' EPS (Basic) (Quarter) stood at -$0.31 in 2021, then crashed by 145.16% to -$0.76 in 2022, then grew by 10.53% to -$0.68 in 2023, then increased by 26.71% to -$0.5 in 2024, then rose by 11.71% to -$0.44 in 2025.
  • Its last three reported values are -$0.44 in Q3 2025, -$0.37 for Q2 2025, and -$0.37 during Q1 2025.